DIVP - ETF AI Analysis
Top Page
Cullen Enhanced Equity Income ETF (DIVP)
Rating:69Neutral
Price Target:―
Positive Factors
Strong Recent Performance
The ETF has shown positive returns over the past month, three months, and year-to-date, indicating solid recent momentum.
Broad Sector Diversification
Holdings are spread across many sectors such as health care, financials, energy, and industrials, which helps reduce the impact of weakness in any single industry.
Multiple Strong Top Holdings
Several of the largest positions, including major energy and health care companies, have delivered strong gains so far this year, supporting the fund’s overall results.
Negative Factors
Moderately High Expense Ratio
The fund’s expense ratio is on the higher side for an ETF, which can gradually reduce net returns for long-term investors.
Heavy U.S. Concentration
With the vast majority of assets in U.S. stocks and very limited exposure to other countries, the fund is highly tied to the U.S. market’s fortunes.
Underperforming Top Holding
At least one major position in the portfolio has shown weak performance this year, which can drag on the ETF’s overall results if the trend continues.
DIVP vs. SPDR S&P 500 ETF (SPY)
AUM55.55M
RegionNorth America
Expense Ratio0.55%
Beta0.44
IssuerCullen
Inception DateMar 06, 2024
Dividend Yield5.92%
Asset ClassEquity
Index TrackedNo Underlying Index
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. Volume8,604
30 Day Avg. Volume14,704
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
30.68Price Target Upside― Downside
Rating ConsensusModerate Buy
Number of Analyst Covering35
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
DIVP Summary
The Cullen Enhanced Equity Income ETF (DIVP) is an actively managed fund that invests across the total U.S. stock market, aiming to provide both growth and regular income. It does not track a specific index, but instead picks a mix of companies in many sectors, including health care, financials, and energy. Well-known holdings include Merck and Exxon Mobil. Someone might consider DIVP to diversify their portfolio while seeking stock market growth plus extra income. A key risk is that it still invests mainly in stocks, so its value can go up and down with the overall market.
How much will it cost me?The Cullen Enhanced Equity Income ETF (DIVP) has an expense ratio of 0.55%, meaning you’ll pay $5.50 per year for every $1,000 invested. This expense ratio is higher than average for ETFs because it is actively managed, requiring more resources to implement its enhanced equity income strategy. Active management often involves more research and trading compared to passively managed funds, which track an index.
What would affect this ETF?The Cullen Enhanced Equity Income ETF (DIVP) could benefit from stable or improving economic conditions in the U.S., as its focus on income-producing assets and diverse sector exposure, including health care, financials, and consumer defensive, supports resilience and growth. However, rising interest rates or regulatory changes affecting key sectors like energy and financials may negatively impact its performance. Additionally, shifts in market sentiment toward income-focused strategies could influence investor demand for this ETF.
DIVP Top 10 Holdings
DIVP leans heavily on U.S. health care and financials, with UnitedHealth and Merck acting as key pillars: UnitedHealth has been rising and giving the fund a solid boost, while Merck’s more mixed recent stretch keeps its impact steadier. On the value side, Citigroup has been a bright spot, climbing and helping offset some bumps. Energy names like EOG Resources and ConocoPhillips have lost a bit of steam lately, and IBM’s lagging share price isn’t helping, but the fund’s broad, U.S.-focused mix keeps any single name from steering the whole ship.
Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
| Merck & Company | 4.17% | $2.30M | $319.99B | 58.36% | 80 Outperform | |
| International Business Machines | 4.08% | $2.25M | $272.12B | 5.41% | 79 Outperform | |
| UnitedHealth | 4.06% | $2.24M | $386.29B | 35.84% | 72 Outperform | |
| Sysco | 3.67% | $2.02M | $40.56B | 10.06% | 71 Outperform | |
| EOG Resources | 3.64% | $2.01M | $69.66B | 8.54% | 78 Outperform | |
| Bristol-Myers Squibb | 3.50% | $1.93M | $118.71B | 23.24% | 78 Outperform | |
| VICI Properties | 3.41% | $1.88M | $29.07B | -18.80% | 73 Outperform | |
| Conocophillips | 3.39% | $1.87M | $127.59B | 13.20% | 78 Outperform | |
| Truist Financial | 3.31% | $1.83M | $63.51B | 13.13% | 70 Outperform | |
| Keurig Dr Pepper | 3.16% | $1.74M | $45.31B | -7.46% | 71 Outperform |
DIVP Technical Analysis
Positive
―
Price Trends
26.51
Positive
26.22
Positive
25.32
Positive
Market Momentum
0.22
Negative
57.91
Neutral
71.14
Neutral
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For DIVP, the sentiment is Positive. The current price of undefined is equal to the 20-day moving average (MA) of 26.90, equal to the 50-day MA of 26.51, and equal to the 200-day MA of 25.32, indicating a bullish trend. The MACD of 0.22 indicates Negative momentum. The RSI at 57.91 is Neutral, neither overbought nor oversold. The STOCH value of 71.14 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for DIVP.
DIVP Peer Comparison
Comparison Results
Performance Comparison
DIVP
Cullen Enhanced Equity Income ETF
27.19
3.03
12.54%
BAMD
Brookstone Dividend Stock ETF
―
―
―
SOVF
Sovereign's Capital Flourish Fund
―
―
―
YALL
God Bless America ETF
―
―
―
RFDA
RiverFront Dynamic US Dividend Advantage ETF
―
―
―
PFOE
Pathfinder Focused Opportunities ETF
―
―
―
Glossary
BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
DisclaimerThis AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―
Table of Contents